Nephrology and Hypertension, Vanderbilt University, Nashville, Tennessee, USA.
Kidney Int. 2013 Aug;84(2):256-64. doi: 10.1038/ki.2012.466. Epub 2013 Feb 13.
The long-term survival for many chronic kidney failure patients who remain treated by dialysis in economically advanced countries remains similar to that of those with solid-organ malignancy, despite a disproportionate amount of health-care expenditure. As such, the current paradigm of three times weekly in-center hemodialysis for 4 h or shorter sessions needs to change to improve patient outcomes. Although more frequent and longer dialysis sessions have been reported to improve cardiovascular risk surrogates and short-term outcomes, these options are only practically available to a very small fraction of the total dialysis population. As such, radically new approaches are required to improve patient outcomes and quality of life for the majority of dialysis patients. Currently, two different approaches are being developed, wearable devices based on current dialysis techniques and more futuristic implantable devices modeled on the natural nephron.
尽管在经济发达的国家,用于治疗慢性肾衰竭患者的医疗支出不成比例,但许多接受透析治疗的患者的长期存活率仍与实体器官恶性肿瘤患者相似。因此,目前每周三次、每次 4 小时或更短时间的中心血液透析治疗模式需要改变,以改善患者的预后。尽管更频繁和更长时间的透析治疗已被报道可以改善心血管风险替代指标和短期预后,但这些选择在实践中仅适用于透析患者总数的一小部分。因此,需要采用全新的方法来改善大多数透析患者的预后和生活质量。目前,正在开发两种不同的方法,一种是基于现有透析技术的可穿戴设备,另一种是基于天然肾单位的更具未来感的植入式设备。